Firefly Neuroscience reports significant growth, expanding its commercial footprint 20-fold and EEG/ERP scan volume by 33-fold.
Quiver AI Summary
Firefly Neuroscience, Inc. has reported a remarkable growth trajectory, announcing a more than 20-fold expansion in its commercial footprint and a 33-fold increase in EEG/ERP brain scan volumes in 2025. This growth is attributed to the acquisition of Evoke Neuroscience and successful internal initiatives, resulting in partnerships with 99 commercial users who conducted over 10,800 brain scans. Firefly's CEO, Greg Lipschitz, emphasized the company’s commitment to leveraging AI and enhanced EEG/ERP technology to revolutionize neuroscience and clinical practices. With a substantial database of over 191,000 standardized EEG/ERP scans, Firefly aims to develop the first foundation model of the human brain to advance the understanding and treatment of neurological and mental disorders.
Potential Positives
- Company reports a greater than 20-fold expansion of its commercial footprint, which indicates significant growth and increased market presence.
- Achieves a 33-fold increase in EEG/ERP brain scan volumes, demonstrating the successful execution of growth strategies and heightened interest in its services.
- Possesses the world's largest standardized EEG/ERP repository with over 191,000 scans, providing a competitive advantage in research and development for brain health solutions.
- Utilization of NVIDIA L40S GPU acceleration to enhance EEG/ERP processing indicates the company's commitment to leveraging cutting-edge technology for advancements in neuroscience.
Potential Negatives
- Despite significant growth in commercial footprint and scan volumes, the reliance on forward-looking statements may raise concerns regarding the company's ability to manage future risks and uncertainties effectively.
- The extensive use of forward-looking statements highlights a level of uncertainty that may lead investors to question the reliability of the company's future projections.
- The need to reference risks and uncertainties may indicate potential vulnerabilities in Firefly’s business strategy and operational execution.
FAQ
What recent milestones has Firefly Neuroscience achieved?
Firefly has expanded its commercial footprint by more than 20 times and increased EEG/ERP brain scan volumes 33-fold.
How has Firefly enhanced its brain scan capabilities?
The company utilized acquired technology and internal initiatives to partner with 99 commercial users and conduct over 10,800 EEG/ERP scans.
What is Firefly's mission regarding brain health?
Firefly aims to leverage AI and EEG/ERP technology to transform neuroscience and clinical development for neurological and mental disorders.
What technological advancements is Firefly utilizing?
Firefly is deploying NVIDIA L40S GPU acceleration to enhance EEG/ERP processing for better cognitive brain biomarker discovery.
What is the significance of Firefly's EEG/ERP database?
With over 191,000 EEG/ERP brain scans, Firefly's database is the largest standardized EEG/ERP repository, revolutionizing diagnostic methods.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AIFF Insider Trading Activity
$AIFF insiders have traded $AIFF stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $AIFF stock by insiders over the last 6 months:
- PRIVATE CAPITAL LP WINDSOR has made 0 purchases and 10 sales selling 400,000 shares for an estimated $1,016,016.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$AIFF Revenue
$AIFF had revenues of $388K in Q3 2025. This is an increase of 1075.76% from the same period in the prior year.
You can track AIFF financials on Quiver Quantitative's AIFF stock page.
$AIFF Hedge Fund Activity
We have seen 5 institutional investors add shares of $AIFF stock to their portfolio, and 16 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG removed 66,015 shares (-72.8%) from their portfolio in Q4 2025, for an estimated $57,763
- JANE STREET GROUP, LLC added 60,315 shares (+inf%) to their portfolio in Q4 2025, for an estimated $52,775
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 37,742 shares (+inf%) to their portfolio in Q4 2025, for an estimated $33,024
- ADVISORY SERVICES NETWORK, LLC removed 31,344 shares (-48.9%) from their portfolio in Q4 2025, for an estimated $27,426
- SAVVY ADVISORS, INC. removed 21,500 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $18,812
- MILLENNIUM MANAGEMENT LLC removed 10,051 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $29,248
- BLACKROCK, INC. added 8,798 shares (+11.4%) to their portfolio in Q4 2025, for an estimated $7,698
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
- Company reports 20-fold expansion of commercial footprint, 33-fold increase in EEG/ERP brain scan volumes -
- Harnessing increased data and cutting-edge supercomputing potentially unlocks new AI-driven biomarker discovery capabilities and significantly advances Firefly on its path of building a foundation model of the human brain -
KENMORE, N.Y., March 04, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce a greater than 20-fold expansion of its commercial footprint, and a 33-fold Increase in its EEG/ERP scan volumes.
Through its acquisition of Evoke Neuroscience, Inc. and the successful execution of its key internal growth initiatives, Firefly ended 2025 partnered with 99 commercial users who completed a total of more than 10,800 EEG/ERP brain scans.
The year-over-year increases in partner sites and EEG/ERP clinical assessments represent growth of 1,880% and 3,227%, respectively, since the end of 2024.
“As demonstrated by this significant expansion of our commercial footprint and meaningful increase in our brain scan volumes, we continue to successfully execute against the key pillars of our growth strategy,” said Greg Lipschitz, Firefly’s Chief Executive Officer. “Our mission is to harness the power of AI and EEG/ERP to transform neuroscience and clinical development. With an exponentially growing foundation of clean data, and by deploying NVIDIA L40S GPU acceleration to power next-generation EEG/ERP processing, the Company believes that it is poised to make additional new breakthroughs in cognitive brain biomarker discovery, and to fulfill its goal of building and launching the world’s first EEG/ERP-based foundation model of the human brain.”
About Firefly
Firefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions designed to provide clinicians and researchers with unparalleled insights into brain function. Firefly’s proprietary database currently consists of over 191,000 EEG/ERP brain scans, making it the world’s largest known standardized EEG/ERP repository. Firefly’s EEG-based, AI-driven, and FDA-510(k)-cleared brain analytics technology has the potential to revolutionize diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD.
Please visit www.fireflyneuro.com for more information.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management team’s expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor & Media Contact
Stephen Kilmer
(646) 274-3580
[email protected]